Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
177 hedge funds and large institutions have $1.18B invested in Intercept Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 54 reducing their positions, and 46 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 54
8% less call options, than puts
Call options by funds: $50.8M | Put options by funds: $55.1M
8% less funds holding
Funds holding: 192 → 177 (-15)
8% less capital invested
Capital invested by funds: $1.28B → $1.18B (-$103M)
30% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$48.2M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$32.2M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$31.9M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$23.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$50.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$26.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.1M |
| 4 |
JP Morgan Chase
New York
|
-$14.9M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$12.6M |
ICPT Hedge Fund Activity: Q3 2020 in Review
177 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2020, worth a combined $1.18B — down 8.1% from $1.28B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of ICPT and 32 opened new positions — a net loss of 14 holders — while 54 trimmed existing stakes and 54 added.
The largest buyer was Boxer Capital, adding an estimated $48.2M. The largest seller was Fidelity Investments, cutting an estimated $50.2M.
- 177 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2020, down from 192 in Q2 2020.
- Funds reported $1.18B of Intercept Pharmaceuticals, Inc. stock for Q3 2020, down 8.1% quarter-over-quarter.
- 32 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2020 and 46 closed out, a net change of -14 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2020 was Boxer Capital, an estimated $48.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2020 was Fidelity Investments, an estimated $50.2M sold.
Based on aggregated 13F filings for Q3 2020.